CN-122017242-A - Application of reagent for detecting marker in preparation of product for predicting prognosis of patient with triple negative breast cancer

Abstract

The invention discloses application of a reagent for detecting a marker in preparation of a product for predicting prognosis of a patient with triple negative breast cancer, wherein the marker is SPB1 protein or a coding gene thereof, and relates to the technical field of detection markers. According to the invention, the result of evaluating the prognosis of the SPB1 protein on the patient with triple negative breast cancer through the ROC curve shows that the AUC value can reach 0.768, which shows that the SPB1 protein can be used as a marker for the prognosis of the patient with triple negative breast cancer.

Inventors

• YU HUI
• LUO HUI
• QIU PU
• SHEN JIAYI
• WANG YUMENG

Assignees

• 广东医科大学附属医院

Dates

Publication Date

20260512

Application Date

20260210

Claims (9)

1. 1. Use of a reagent for detecting a marker in the preparation of a product for predicting prognosis of a patient with triple negative breast cancer, characterized in that the marker is an SPB1 protein or a gene encoding the same.
2. 2. The use according to claim 1, wherein the reagent for detecting a marker is a reagent based on an immunohistochemical staining method, a reagent based on a specific antibody detection method, a reagent based on a mass spectrometry detection method, a reagent based on a label free proteomics detection method or a reagent based on a molecular biology detection method.
3. 3. The use according to claim 2, wherein the reagents based on immunohistochemical staining method comprise buffer or staining reagents, the reagents based on specific antibody detection method comprise anti-SPB 1 antibodies, and the reagents based on mass spectrometry method comprise pancreatin, reducing agent, alkylating agent or desalting column.
4. 4. The use according to claim 1, wherein the product assesses prognosis by detecting the expression level of SPB1 protein or its encoding gene in a sample.
5. 5. The use according to claim 4, wherein the expression level of the SPB1 protein or the gene encoding it is inversely related to the prognosis of a triple negative breast cancer patient.
6. 6. The use of claim 4, wherein the prognosis comprises one or more of total survival, disease-free survival, risk of disease progression.
7. 7. The use according to claim 1, wherein the sample is a tumor tissue sample or a paracancestor tissue sample of a triple negative breast cancer patient.
8. 8. The use according to claim 1, wherein the product is detected by one or more of immunohistochemistry, western blotting, enzyme-linked immunosorbent assay, immunofluorescence techniques, real-time fluorescent quantitative PCR.
9. 9. The use according to any one of claims 1 to 8, wherein the product is a detection reagent or a detection kit.

Description

Application of reagent for detecting marker in preparation of product for predicting prognosis of patient with triple negative breast cancer Technical Field The invention relates to the technical field of detection markers, in particular to application of a reagent for detecting markers in preparation of a product for predicting prognosis of a patient with triple negative breast cancer. Background Breast cancer is a common malignant tumor type for women worldwide, and the prognosis heterogeneity thereof significantly affects the accurate decision of clinical treatment. Current prognostic assessment is largely dependent on histopathological grading, TNM staging and traditional molecular markers (e.g. Ki-67, ER, PR, HER status). However, these indicators are particularly limited in prognosis value among the most aggressive and lacking effective therapeutic targets of Triple Negative Breast Cancer (TNBC), making accurate risk stratification and personalized treatment guidance for TNBC patients difficult. Therefore, the development of novel specific prognostic markers based on the molecular mechanisms specific to TNBC has an urgent real need for improving clinical management of patients in this high-risk subpopulation. Polyamine metabolic reprogramming has been widely demonstrated as a core mechanism supporting rapid proliferation of tumors, its association with tumor cell cycle progression, resistance to apoptosis, and microenvironment remodeling. The research shows that key regulating factors of polyamine steady state can drive malignant tumor progress by influencing MYC, MAPK and other signal paths, and are closely related to chemotherapy resistance. In recent years, advances in metabonomics and molecular biology technology have enabled systematic resolution of tumor-specific metabolic dependencies, for example, key roles for ODC1 in polyamine synthesis have been established as therapeutic targets for a variety of cancers, while SAT1 expression levels have been demonstrated to be correlated with patient survival in part of solid tumors. However, the above studies have focused on classical synthesis and catabolic enzymes of the polyamine pathway, for which upstream or co-regulatory proteins, especially factors with unique binding and transport functions, are still significantly under-studied in the function and mechanism of specific cancer species (e.g., TNBC). SPB1 (Spermine Binding Protein 1) is used as an important regulator of intracellular polyamine homeostasis, and the prior research mainly focuses on the basic functions of regulating cell growth and differentiation by binding polyamine with high affinity and affecting the size of a free polyamine pool in cells. However, its specific role in the development of malignant tumors, particularly TNBC, has long been ignored. In the prior art, the research on SPB1 mainly stays at the basic biochemical characteristic level, whether specific expression or functional activation occurs in TNBC is not clarified, and the substantial research for systematically verifying the association of protein levels (especially specific functional forms) and TNBC patient prognosis and treatment response in a clinical queue is absent, which constitutes an important knowledge gap and technical bottleneck for converting polyamine metabolism regulation networks into TNBC clinical practice. Disclosure of Invention Aiming at the technical bottleneck, the invention discloses that the SPB1 protein has obvious negative correlation with the prognosis of the patient with triple negative breast cancer, and can be used as a marker of the prognosis of the patient with triple negative breast cancer. In order to achieve the above purpose, the technical scheme of the invention is as follows: In a first aspect of the invention, the application of a reagent for detecting a marker in the preparation of a product for predicting prognosis of a patient with triple negative breast cancer is provided, wherein the marker is SPB1 protein or a coding gene thereof, and the sequence of the marker is shown as SEQ ID NO. 1. Further, in the above application, the reagent for detecting the marker is a reagent based on an immunohistochemical staining detection method, a reagent based on a specific antibody detection method, a reagent based on a mass spectrometry detection method, a reagent based on a label free proteomics detection method or a reagent based on a molecular biology detection method. Further, in the above application, the reagent based on the immunohistochemical staining method comprises a buffer solution or a staining reagent, the reagent based on the specific antibody detection method comprises an anti-SPB 1 antibody, and the reagent based on the mass spectrometry detection method comprises pancreatin, a reducing agent, an alkylating agent or a desalting column. Further, in the above application, the product evaluates prognosis by detecting the expression level of SPB1 protein or its encoding gene